April19 is a drug development company that leverages artificial intelligence (AI) and computational chemistry to innovate psychedelic-inspired compounds aimed at addressing not only mental health issues but also neurodegenerative conditions and promoting healthy longevity. The company focuses on optimizing psychedelics based on unique pharmacological insights derived from academic research. By integrating advanced AI-driven computational models, April19 aims to explore a vast chemical space to identify and develop compounds that can provide therapeutic benefits, particularly for cognitive decline and dementia, which are increasingly pressing concerns in an aging population.

The company is also addressing the limitations of existing psychedelic treatments, which often involve high-dose therapies that may not be suitable for elderly patients. April19 is exploring alternatives such as "nonpsychedelic psychedelics" or psychoplastogens, which are designed to offer therapeutic effects without the hallucinogenic properties of traditional psychedelics. Their drug design platform utilizes AI to efficiently screen billions of potential compounds, predict molecular properties, and optimize drug candidates, thereby enhancing the likelihood of developing safe and effective treatments for neurodegenerative disorders. This innovative approach aims to reduce tolerance buildup and cardiotoxicity risks, making long-term pharmacotherapy more feasible for vulnerable populations.

Canada

We use next-gen machine learning to find novel psychedelic drug compounds. Classical (first-generation) psychedelics have never been optimized to treat any disease and so we aim to design compounds with the optimal risk-benefit ratio in various indications. Beyond mental health, we focus on neurodegeneration and neural injuries, increasing brain longevity and extending human mental healthspan.

April 19

Company Details